Cystic Fibrosis Community Celebrates New Treatment Option

The cystic fibrosis community received news worth celebrating this week.


The Food and Drug Administration approved a new drug that helps address the underlying cause of cystic fibrosis, not simply its symptoms.  The drug, a combination of tezacaftor/ivacaftor, is for patients aged 12 and older with certain cystic fibrosis mutations.

 Read more from Institute for Patient Access